Eli Lilly and Company
LLY · Healthcare · $1.1T
After-hours $1,150.18-0.11%
Price
$1200.1
$1149.8
Jul 6, 26Oct 1, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$22.2B-3.5%
6/'26 vs prev quarter
Company Health
Market Cap$1.1T
Operating Margin+43.9%
Cash on Hand$8.9B0.8% of market cap
Free Cash Flow$12.3B1.1% of market cap
Among 19 Drug Manufacturers - General peers
LowMedianHigh
PSR13.6xmedian 3.3xPER40.6xmedian 22.8xPBR32.0xmedian 5.0xROE+78.8%median +22.8%Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal13h ago
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart17h ago
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes studyYesterday
Experimental Lilly combination drug tops Zepbound in weight-loss trialYesterday
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesYesterday
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new studyYesterday
